Who owns LEAP THERAPEUTICS INC?
- Ticker: LPTX
- CUSIP Number: 52187k200
Tip: Access positions for across all investors
Analyze quarterly positions in Leap Therapeutics with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Leap Therapeutics stock
Who bought or sold LEAP THERAPEUTICS INC this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| Baker Bros. Advisors | 1.2M | $3.1M | 0% | Mar 2024 |
|
| Rock Springs Capital Management | 912k | $2.4M | -15% | Mar 2024 |
|
| Vanguard Group | 868k | $2.3M | 112% | Mar 2024 |
|
| Citadel Advisors | 729k | $1.9M | 1% | Mar 2024 |
|
| Balyasny Asset Management | 671k | $1.8M | 100% | Mar 2024 |
|
| Samsara BioCapital | 669k | $1.8M | 0% | Mar 2024 |
|
| Adage Capital Partners GP | 480k | $1.3M | -49% | Mar 2024 |
|
| 683 Capital Management | 450k | $1.2M | 0% | Mar 2024 |
|
| Simplify Asset Management | 376k | $1.0M | 100% | Mar 2024 |
|
| Acadian Asset Management | 282k | $750k | 100% | Mar 2024 |
|
| Key Client Fiduciary Advisors | 233k | $620k | 9% | Mar 2024 |
|
| Geode Capital Management | 203k | $539k | 41% | Mar 2024 |
|
| UBS O'Connor | 107k | $286k | 100% | Mar 2024 |
|
| Dimensional Fund Advisors | 66k | $175k | 100% | Mar 2024 |
|
| Northern Trust | 45k | $120k | 61% | Mar 2024 |
|
| Logos Global Management | 40k | $105k | 100% | Mar 2024 |
|
| XTX Topco | 37k | $99k | 200% | Mar 2024 |
|
| Susquehanna International | 30k | $78k | 53% | Mar 2024 |
|
| BlackRock | 29k | $78k | -35% | Mar 2024 |
|
| Squarepoint Ops | 27k | $72k | 100% | Mar 2024 |
|
| Marshall Wace | 22k | $58k | 100% | Mar 2024 |
|
| Goldman Sachs Group | 18k | $49k | 100% | Mar 2024 |
|
| Millennium Management | 15k | $40k | 100% | Mar 2024 |
|
| American Century Companies | 11k | $28k | 100% | Mar 2024 |
|
| Tower Research Capital | 6.6k | $18k | 146% | Mar 2024 |
|
| Advisor Group Holdings | 4.6k | $12k | -10% | Mar 2024 |
|
| Baystate Wealth Management | 3.4k | $14k | 124% | Dec 2023 |
|
| Simplex Trading | 2.3k | $6.0k | -91% | Mar 2024 |
|
| CNB Bank | 1.5k | $4.0k | 0% | Mar 2024 |
|
| Atlantic Trust | 1.5k | $4.1k | 100% | Mar 2024 |
|
| Morgan Stanley | 1.1k | $2.9k | 10% | Mar 2024 |
|
| Group One Trading | 811.00 | $2.2k | -68% | Mar 2024 |
|
| Us Bancorp | 610.00 | $1.6k | 0% | Mar 2024 |
|
| Jpmorgan Chase & Co | 227.00 | $604.001600 | -15% | Mar 2024 |
|
| Wells Fargo & Company | 152.00 | $404.000800 | 2% | Mar 2024 |
|
| Tompkins Financial Corp | 120.00 | $318.996000 | 0% | Mar 2024 |
|
| Hanson McClain Advisors | 115.00 | $306.003500 | 0% | Mar 2024 |
|
| Rhumbline Advisers | 24.00 | $63.000000 | 0% | Mar 2024 |
|
| Qube Research & Technologies | 6.00 | $16.000200 | 100% | Mar 2024 |
|
| Caldwell Sutter Capital | 4.00 | $11.000000 | 0% | Mar 2024 |
|
Who sold out of Leap Therapeutics?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| T. Rowe Price Associates | Dec 2023 | 119k | $495k |
| Alyeska Investment Group | Dec 2023 | 51k | $213k |
| Perceptive Advisors | Dec 2023 | 45k | $186k |
| T. Rowe Price Investment Management | Sep 2023 | 35k | $49k |
| Hrt Financial | Dec 2023 | 13k | $53k |
| Annandale Capital | Sep 2023 | 2.0k | $3.0k |
| UBS Group | Dec 2023 | 814.00 | $3.4k |
| Bank of America Corporation | Dec 2023 | 531.00 | $2.2k |
| Royal Bank of Canada | Dec 2023 | 373.00 | $2.0k |